Answers are grounded in this paper and cite their sources.
Reports effectiveness and safety of a chemotherapy-free regimen in elderly patients with B-cell lymphoma, suggesting a viable treatment option.
The outcomes of elderly patients with lymphoma are poor. There is scarcity of data on outcomes of chemotherapy-free regimens in patients older than 80 years with a B-cell lymphoma. We report three octogenarians with B-cell NHL and the efficacy and safety of a nonchemotherapy regimen using a lower dose of polatuzumab vedotin and anti-CD20 monoclonal antibody. No infusion-related adverse events were noted. No patient developed neutropenia. Peripheral neuropathy was grade 2 in all cases. Recurrent UTI were a concern in two patients. After a median of 6 cycles (range 1-6) of polatuzumab therapy, all three patients had achieved CR. One patient was lost to follow-up and succumbed to a multidrug-resistant gram-negative UTI. One patient relapsed at 13 months and other is doing well in remission at 15 months.
No takes yet. Share an insight, caveat, or question.
Chakravorty et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: